**Acute sports injury repair** is the most common application scenario, with treatment typically lasting 2-4 weeks. For acute injuries such as muscle strains and tendon micro-tears, daily subcutaneous injections of 250-500 μg for two weeks are effective. Clinical data show that during this course of treatment, the level of inflammatory cytokines at the injury site can be reduced by 40%-50%, and the repair speed is 30% faster than natural recovery. Therefore, this method is particularly suitable for athletes with acute injuries during competition. For more severe injuries (such as grade II tendon strains), the treatment cycle can be extended to four weeks, but the dose should be halved from the third week to avoid local reactions.
Treatment of chronic injuries requires a 6-8 week course of treatment, supplemented by rehabilitation training. For chronic conditions such as long-term rotator cuff tears and knee cartilage wear, BPC157 requires a longer fibroblast activation course. Typically, 500 μg is injected daily for the first four weeks, followed by injections every other day for the next four weeks. During this period, low-intensity rehabilitation training (such as joint range of motion exercises) is incorporated to achieve the dual effects of "repair and functional recovery." Studies have shown that this combination therapy of "medication + rehabilitation" can reduce the recurrence rate of chronic injuries by 55%.
In the fitness field, preventative use is the shortest, typically only one to two weeks. Some high-intensity trainees take 250 micrograms daily one to two weeks before their peak training period (such as the final sprint of a competition). The aim is to enhance the injury resistance of tendons and ligaments and reduce the accumulation of micro-damage caused by overtraining. However, long-term safety data for this method is currently lacking and requires careful evaluation.
It is worth noting that there is currently no officially recommended treatment cycle for BPC157, and individual differences are significant: patients weighing over 80 kg may need to increase the dosage, while patients sensitive to peptide drugs may see significant effects within a week. Sports rehabilitation experts emphasize that "the design of the treatment cycle should follow the principle of 'stopping medication once the rehabilitation goal is achieved.' Blindly extending the treatment cycle will not only not bring additional benefits but may also increase the risk of local redness and swelling at the injection site. The treatment plan must be dynamically adjusted according to the injury recovery progress."